Monoclonal antibody-based therapies are improving outcomes for patients with a range of cancers
Anti-cancer immunotherapy, including monoclonal antibodies to specific cell surface protein antigens, is proving to be a successful strategy in the emerging era of personalised medicine. This issue of the Journal includes the report of a retrospective study of the impact of one of the first therapeutic monoclonal antibodies, rituximab, on the relative survival of patients with non-Hodgkin lymphoma in Queensland between 1993 and 2012.1 Rituximab binds the CD20 antigen that is found on 90% of B cells, making it easier for other immune system cells to eliminate the cancerous cells (antibody-dependent cell-mediated immunity).
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Wright F, Hapgood G, Loganathan A, et al. Relative survival of patients with lymphoma in Queensland according to histological subtype. Med J Aust 2018; 209: 166-172.
- 2. Mannetje A, De Roos AJ, Boffetta P, et al Occupation and risk of non-Hodgkin lymphoma and its subtypes: a pooled analysis from the InterLymph consortium. Environ Health Perspect 2016; 124: 396-405.
- 3. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival form NSABP B-31 and NCCTG N9831. J Clin Oncol 2014; 32: 3744-3752.
- 4. Zugmaier G, Gökbuget N, Klinger M, et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood 2015; 126: 2578-2584.
- 5. Shen K, Ma X, Zhu C, et al. Safety and efficacy of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-postive breast cancer: a meta-analysis. Sci Rep 2016; 6: 23262.
- 6. Auger-Quittet S, Duny Y, Daures J-P, Quittet P. Outcomes after 90yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis. Cancer Med 2014; 3: 927-938.
- 7. Botrel TE, Clark L, Paladini L, Clark O. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer. BMC Cancer 2016; 16: 667.
- 8. Greiller L, Tomasini P, Barlesi F. Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience. Ther Adv Respir Dis 2016; 10: 485-491.
- 9. Letendre P, Monga V, Mihem M, Zakharia Y. Ipilimumab: from preclinical development to future clinical perspectives in melanoma. Future Oncol 2017; 13: 625-636.
- 10. Medina PJ, Adams VR. PD-1 pathway inhibitors: immune-oncology agents for restoring antitumour immune responses. Pharmacotherapy 2016; 36: 317-334.
- 11. Ning YM, Suzman D, Maher VE, et al. FDA approval summary: atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy. Oncologist 2017; 22: 743-749.
No relevant disclosures.